Key clinical point: PD-L1 positive status in the tumor and negative status in the thrombus is linked to aggressive behavior in clear cell renal cell carcinoma.
Major finding: PD-L1 immunostaining was positive in at least one of the three samples of the main tumor in 22 of 39 advanced clear cell renal cell carcinomas. Cases that lost PD-L1 positivity in the thrombus (18 cases), were of higher grade (Fisher's exact test, P = 0.01) and higher AJCC pT category (Cochran Armitage, P = 0.02) than the cases that were positive both in tumor and thrombus (4 cases). A high variability in PD-L1 positivity was noted across three different areas of the main tumor tested. This variability should be kept in mind when selecting the tumor samples to be tested for determining immunotherapy.
Study details: An analysis of PD-L1 (SP142) expression in three different areas of the tumor and in two areas of the renal vein/caval thrombi in 39 advanced clear cell renal cell carcinomas.
Disclosures: The researchers reported no relevant financial disclosures.
Source: Lopez J et al. Annals of Diagnostic Pathology June 2018, Pages 89-93 https://doi.org/10.1016/j.anndiagpath.2018.03.007
Lopez J et al. Annals of Diagnostic Pathology June 2018, Pages 89-93 https://doi.org/10.1016/j.anndiagpath.2018.03.007
This Week's Must Reads
Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019
Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055
Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022
High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.
Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.
Must Reads in Renal Cell Carcinoma
In mRCC: Sunitinib alone not inferior to nephrectomy-sunitinib, Méjean A et al. N Engl J Med. 2018 Aug 2. doi: 10.1056/NEJMoa1803675.
Proactive management eases side effects of sunitinib treatment in RCC, Staehler M et al. Ann Oncol. 2018 Aug 23. doi: 10.1093/annonc/mdy329
Red cell distribution width might predict cancer-specific survival in RCC , Życzkowski M et al. Clinical Genitourinary Cancer 2018 June (16), e677-e683. https://doi.org/10.1016/j.clgc.2017.12.003
mRCC: Patients survive longer at high-volume centers, Joshi SS et al. Euro Urol. 2018 Sep;74:387-93.
High PD1 mRNA levels tied to anti-PD1 monotherapy response, Paré L et al. Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy335.